Event Panel Schedule

Brian Culley, CEO/Interim CFO / Lineage Cell Therapeutics Inc. Info

Mr. Culley joined Lineage Cell Therapeutics as CEO in September 2018. Prior to joining Lineage Cell Therapeutics, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he… [show more]

Mr. Culley joined Lineage Cell Therapeutics as CEO in September 2018. Prior to joining Lineage Cell Therapeutics, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University. [hide]

Brandi Roberts, Chief Financial Officer / Lineage Cell Therapeutics Inc. Info

Ms. Roberts joined Lineage as Chief Financial Officer in January 2019. Prior to joining Lineage, Ms. Roberts served from August 2017 to January 2019 as Chief Financial Officer at REVA Medical, Inc. Ms. Roberts previously served as Chief Financial… [show more]

Ms. Roberts joined Lineage as Chief Financial Officer in January 2019. Prior to joining Lineage, Ms. Roberts served from August 2017 to January 2019 as Chief Financial Officer at REVA Medical, Inc. Ms. Roberts previously served as Chief Financial Officer at Mast Therapeutics, Inc. (MSTX), a publicly traded US-based biopharmaceutical company, from January 2013 to April 2017, having served as its Senior Vice President, Finance from March 2011 to January 2013. Previously, she held senior positions at Alphatec Spine, Artes Medical, Stratagene and Pfizer. Ms. Roberts brings more than 24 years of public accounting and finance experience, including 21 years at publicly traded pharmaceutical, medical technology, and life science companies to her position. Ms. Roberts is a certified public accountant with the State of California and received her B.S. degree in business administration from the University of Arizona and her M.B.A. from the University of San Diego. Ms. Roberts has served on the Board of Temple Therapeutics BV since November 2019. She also currently serves as Chair of the Southern California Chapter of the Association of Bioscience Financial Officers. [hide]

Joseph Pantginis, Ph.D., Director of Research, Managing Director / H.C. Wainwright & Co., LLC Info

Dr. Pantginis has over 20 years of sell-side experience covering biotechnology companies, having spent most of those years at ROTH Capital Partners and Canaccord Adams. Prior to his sell-side career, he worked at Regeneron Pharmaceuticals, where he… [show more]

Dr. Pantginis has over 20 years of sell-side experience covering biotechnology companies, having spent most of those years at ROTH Capital Partners and Canaccord Adams. Prior to his sell-side career, he worked at Regeneron Pharmaceuticals, where he founded the Retrovirus Core Facility, providing molecular biology service and retroviral vectors to a broad range of Regeneron's research programs. His therapeutic focus is oncology, as well as regenerative medicine and gene therapy. He is also widely recognized for his expertise in cancer immunotherapy as a therapeutic approach to treating cancer. Dr. Pantginis received a B.S. in Biology from Fordham University, an M.B.A. in finance from Pace University, and a Ph.D. in Molecular Genetics from the Albert Einstein College of Medicine. [hide]